One such example occurs in estrogen receptor-positive breast cancer, where the developed loss of ARID1A expression reduces the ability of estrogen to bind and thus decreases the therapeutic efficacy of selective estrogen receptor modulators[27]. The gene discussed is ESR1; the disease is breast carcinoma.